Last updated: May 29, 2026

Application No. 18/299,220

METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS

Non-Final OA

Filed

Apr 12, 2023

Priority

Dec 16, 2016 — provisional 62/435,127 +3 more

Examiner

GIBBS, TERRA C

Art Unit

1635

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Alnylam Pharmaceuticals, Inc.

OA Round

3 (Non-Final)

Interview Optional

— +10.6% interview lift. Interview lift (+10.6%) is below the 15.0% threshold. A written response is recommended.

Based on 953 resolved cases, 2023–2026

Examiner Intelligence

GIBBS, TERRA C View full profile →

Grants 64% of resolved cases

Career Allowance Rate

611 granted / 953 resolved

+4.1% vs TC avg

Moderate +11% lift

Without

With

+10.6%

Interview Lift

resolved cases with interview

Typical timeline

2y 8m

Avg Prosecution

36 currently pending

Career history

992

Total Applications

across all art units

Statute-Specific Performance

§101

6.2%

-33.8% vs TC avg

§103

51.6%

+11.6% vs TC avg

§102

9.2%

-30.8% vs TC avg

§112

15.4%

-24.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 953 resolved cases

Prosecution Timeline

Apr 12, 2023

Application Filed

Jun 20, 2024

Non-Final Rejection mailed

Oct 16, 2024

Response Filed

Oct 28, 2024

Final Rejection mailed

Apr 25, 2025

Notice of Allowance

Jul 25, 2025

Request for Continued Examination

Jul 28, 2025

Response after Non-Final Action

Mar 25, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/602,765

Patent 12638451

GENETIC AMPLIFIED TUMOR HOMING NANOPARTICLES AND COMPOSITIONS AND METHODS THEREOF

4y 7m to grant Granted May 26, 2026

18/026,388

Patent 12637676

TREATMENT OF OPTIC ATROPHY

3y 2m to grant Granted May 26, 2026

18/062,422

Patent 12637672

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

3y 5m to grant Granted May 26, 2026

17/251,395

Patent 12606829

COMPOSITIONS FOR HERPESVIRUS TRANSCRIPTIONAL FEEDBACK CIRCUIT DISRUPTION AND USES THEREOF

5y 4m to grant Granted Apr 21, 2026

17/502,816

Patent 12600998

Large Scale Synthesis of Messenger RNA

4y 6m to grant Granted Apr 14, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

64%

Grant Probability

75%

With Interview (+10.6%)

2y 8m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 953 resolved cases by this examiner. Grant probability derived from career allowance rate.